Abstract
Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1s ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.
Keywords: extracellular matrix (ECM), matrix metalloproteinases, Experimental Crescentic Glomerulonephritis, unilateral ureteral obstruction, transforming growth factor beta
Current Drug Targets
Title: PAI-1 as a Target in Kidney Disease
Volume: 8 Issue: 9
Author(s): Yufeng Huang and Nancy A. Noble
Affiliation:
Keywords: extracellular matrix (ECM), matrix metalloproteinases, Experimental Crescentic Glomerulonephritis, unilateral ureteral obstruction, transforming growth factor beta
Abstract: Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1s ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.
Export Options
About this article
Cite this article as:
Huang Yufeng and Noble A. Nancy, PAI-1 as a Target in Kidney Disease, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662373
DOI https://dx.doi.org/10.2174/138945007781662373 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Models for the Study of Angiogenesis
Current Pharmaceutical Design Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy Molecules to Selectively Target Receptors for Treatment of Pain and Neurogenic Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Mitochondrial Dynamics: An Emerging Paradigm in Ischemia-Reperfusion Injury
Current Pharmaceutical Design MicroRNA-155 Functions as a Negative Regulator of RhoA Signaling in TGF-β-induced Endothelial to Mesenchymal Transition
MicroRNA Heart Failure in North America
Current Cardiology Reviews Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Reactions of Water-Soluble Alkylperoxyl Radicals and Superoxide with DNA, Lipoproteins and Phospholipid Vesicles:The Role Played by Electrostatic Forces
Current Medicinal Chemistry Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine